AI Article Synopsis
- The study explores the challenges faced by drug-addicted mothers transitioning into parenthood, highlighting the limited research on this topic.
- Participants were 24 mothers aged 25-42 on methadone, with children aged 1-32 months, and data was collected through semi-structured interviews analyzed using Grounded Theory.
- A key finding is the ambivalence these mothers experience regarding their dual roles, leading to feelings of guilt and resulting in a functional approach to motherhood with minimal engagement beyond basic caregiving, although social support, particularly from partners, offers some positive influence.
Article Abstract
This is a study about balancing motherhood and drug addiction, during the transition to parenthood. Few studies have dealt with the parental experience of drug-addicted mothers. The participants included 24 drug-addicted mothers, on methadone, with ages 25-42 and with children 1-32 months of age. Semi-structured interviews were conducted and analyzed according to Grounded Theory. The mothers' main concern was the ambivalence they felt towards pregnancy/motherhood and drug addiction, which was associated with strong feelings of guilt. Confronted with this ambivalence their maternal role becomes merely functional. They focus on providing the basic care to the child, but show little willingness to talk or play. Social support, especially from the partner seems to have a positive role.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1359105312443399 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of extra-familial factors in adolescence for the association between out-of-home care and adult psychiatric disorders-A birth cohort study.
PLoS One
January 2025
Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
Background: Psychiatric disorders are a substantial public health concern, and childhood adversity a well-known risk factor for it. Investigating gender differences in vulnerability and resilience processes following out-of-home care (OHC) as proxy for childhood adversity can help map opportunities for the prevention of psychiatric disorders.
Methods: We followed a large birth cohort for psychiatric disorders (anxiety, depression, and self-harm, and substance misuse) between age 25-62 years, comparing individuals with and without OHC experience.
Brain Function Outcomes of Recent and Lifetime Cannabis Use.
JAMA Netw Open
January 2025
Laboratory of NeuroImaging, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland.
Importance: Cannabis use has increased globally, but its effects on brain function are not fully known, highlighting the need to better determine recent and long-term brain activation outcomes of cannabis use.
Objective: To examine the association of lifetime history of heavy cannabis use and recent cannabis use with brain activation across a range of brain functions in a large sample of young adults in the US.
Design, Setting, And Participants: This cross-sectional study used data (2017 release) from the Human Connectome Project (collected between August 2012 and 2015).
Effectiveness of a Dentist-based Anti-Smoking Intervention Among Malaysian Adolescents: A Randomized Controlled Field Trial.
Asian Pac J Cancer Prev
January 2025
Department of Community Oral Health and Clinical Prevention, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Background: The KOTAK program is a national public health initiative in Malaysian primary and secondary schools aimed at reducing youth smoking through school dental services. This study evaluated its effectiveness in Seremban, Negeri Sembilan, Malaysia.
Objectives: 1) To determine the percentage of schoolchildren who quit smoking through the KOTAK program; 2) To identify factors associated with quitting smoking in the program.
Larsucosterol for the Treatment of Alcohol-Associated Hepatitis.
NEJM Evid
February 2025
DURECT Corporation, Cupertino, CA.
Background: Larsucosterol is a DNA methyltransferase inhibitor in development for alcohol-associated hepatitis (AH), a disease for which there is no approved therapy.
Methods: In this phase 2b trial, patients with severe AH were randomly assigned 1:1:1 to receive 30 mg or 90 mg of larsucosterol or placebo; a second dose was administered after 72 hours if the patient remained hospitalized. All patients received supportive care as determined by investigators.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!